In the touchOPHTHALMOLOGY Fall issue of US Ophthalmic Review, Dr Alay Banker published an interesting review on "Emerging Treatments for Non-infectious Uveitis". In this interview at AAO 2018, he discusses the side effects associated with steroidal treatments and how this impacts patient adherence. It is hoped that emerging non-steroidal drugs can alleviate some of these issues. Dr Banker describes the promising discovery of new pathways to target retinal diseases and new cost-effective drugs. He also points out that, unfortunately, the advent of biosimilars in retinal diseases is lagging behind that of other therapeutic areas, particularly in the case of biosimilar anti-vascular endothelial growth factor (anti-VEGF) and biosimilar biologics. Finally, Dr Banker highlights some of the topics he has found most interesting at this year’s AAO meeting, including new imaging techniques and drug delivery systems.
1. Please give a brief introduction to your article from our Fall issue of US Ophthalmic Review, ‘Emerging Treatments for Non-infectious Uveitis’. (0:11)
2. What do you think are the most promising areas of research or therapies in this area for the future? (1:16)
3. What are your key highlights from this year’s American Association of Ophthalmology (AAO) meeting? (2:18)
Speaker disclosures: Alay Banker has nothing to disclose in relation to this interview.
Filmed at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting, Chicago, IL, US, 27–30 October 2018.